Crystagen
Glu-Asp-Pro (immune bioregulator)
Crystagen (Glu-Asp-Pro (immune bioregulator)) is a longevity & bioregulators research compound. Khavinson immune bioregulator — Glu-Asp-Pro, one of the three short peptides this school names as constituents of the thymus preparation Thymalin, proposed to shift gene expression in immune tissue.
Crystagen quick facts
| Reported research dose | 2mg-5mg (per course) |
| Route | Subq |
| Frequency | 1x Daily · Daily (course) |
| Half-life | ~15-30 min |
| Forms | Injectable |
| Evidence level | Russian studies; limited |
Immune/thymic bioregulator — course-based. One of the three short peptides this school names as making up the thymus preparation Thymalin — which is where the human data for it actually comes from. Course pattern: roughly 10 days on, then off, once or twice a year. To know whether it did anything, CBC with differential — and be honest that a peptide split out of a 3-component mixture is hard to attribute anything to. Run it as an experiment you measure, not a protocol you trust.
How Crystagen works
Khavinson immune bioregulator — Glu-Asp-Pro, one of the three short peptides this school names as constituents of the thymus preparation Thymalin, proposed to shift gene expression in immune tissue.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Crystagen
Buy Crystagen at RUPharma →Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Crystagen
Graded by what exists behind each claim.
Human clinical evidence
- The human record is Soviet and post-Soviet clinical work — real patients and real endpoints, published in Russian and rarely replicated to Western standards.
📊 Correlative data
- Positioned for immune regulation. Very little practical record exists outside the Russian literature, and it is one of the least-used items in the series.
- Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 Theoretical / extrapolated
- Glu-Asp-Pro — a synthetic tripeptide in the immune arm of the series, proposed to normalize gene expression in immune and neural tissue.
- The shared claim across the Khavinson series: peptides this short are proposed to enter the cell nucleus and bind promoter regions of DNA, shifting tissue-specific gene expression.
- Two things at once: the mechanism is a real, testable hypothesis with published cell-level work behind it, and essentially all of that work is one group's, unreplicated at scale.
What community dosing logs are worth → · How to read the Soviet clinical series → · The Khavinson series, in full →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Crystagen actually does
First, a correction to this site's own catalog line. The record here has carried Crystagen as a CNS bioregulator in the Epithalon family. It is not one. Glu-Asp-Pro is a peptide of the thymic and immune arm of this series, and the reason the label drifted is instructive: the sequence field previously held Glu-Asp-Arg, which is Pinealon's, and Pinealon genuinely is a brain peptide. One wrong residue moved a product to the wrong organ. The sequence is now Glu-Asp-Pro and the description on this page follows the sequence.
What EDP actually is, in the peer-reviewed record. Thymalin is the thymus polypeptide preparation this school has published on since the 1970s, and its own reviews name its active short peptides explicitly: the dipeptide Lys-Glu, the dipeptide Glu-Trp, and the tripeptide Glu-Asp-Pro. So Crystagen is not a peptide in search of a rationale. It is 1 of the 3 named components of a preparation with an actual clinical record, and that is a stronger starting position than most items in this catalog have.
The molecule, and its one unusual feature. Glu-Asp-Pro, formula C14H21N3O8, average mass 359.35 Da, isoelectric point 3.55, computed net charge about −2.06 at blood pH. Three residues, so it sits inside the di- and tripeptide substrate range described for the PEPT and LAT carriers this group proposes as the route into a cell Khavinson 2022 — unlike the 4-residue members of the catalog, which sit outside it. The 2023 assessment that scored 26 of these peptides against those transporters was molecular docking against all 8,400 possible di- and tripeptides and measured no uptake in a living cell Khavinson 2023, so this remains an argument from structure rather than a measurement.
The proline is the whole story and nobody tells it. Proline is not an ordinary residue. Its side chain loops back onto the backbone nitrogen, which locks the local geometry and removes the amide hydrogen that every other residue uses to donate a hydrogen bond. Two consequences follow directly, and both are checkable. One: a C-terminal proline blocks the common carboxypeptidases, and chewing in from the other end leaves Asp-Pro, a dipeptide that needs prolidase specifically. On chemistry alone, EDP should survive in serum longer than its siblings Glu-Asp-Gly and Glu-Asp-Leu, which have no such protection. Two: the Asp-Pro bond is the most acid-labile bond in peptide chemistry — it is used deliberately as a chemical cleavage site under mild acid — so this particular tripeptide is the one member of the family with a structural reason to be destroyed in the stomach. That is a real argument for the injectable route over a capsule, and it applies to this molecule and not to the others.
Cell, rodent, human — and where it stops
The human data exists, and it is not about this product. This is the same trap the Epitalon pages on this site already have to navigate, running in the opposite direction. There, a tetrapeptide borrows the clinical record of Epithalamin, the pineal extract. Here, a tripeptide sits inside Thymalin, the thymus preparation, and Thymalin has a genuine clinical record: severe COVID-19 in older patients, with reported effects on immune status and on markers of coagulation and inflammation (Kuznik and colleagues, Advances in Gerontology, 2021, in the sources below); and the long elderly series in which thymus and pineal preparations were injected over 6 to 8 years Khavinson 2003. Every one of those results belongs to the mixture. No published human study has given Glu-Asp-Pro on its own to anybody.
In cells. The tissue-culture record for this family runs through the 2021 gene-expression review, which is where the claim that these peptides reach chromatin and contact histones comes from Khavinson 2021, and through the structural search for how a peptide this short could recognize a specific double-stranded DNA sequence at all Kolchina 2019. Named results for EDP specifically are thin next to what exists for Lys-Glu and for the tetrapeptides; the Thymalin reviews describe the 3 component peptides together, attributing gene expression, heat-shock protein synthesis, cytokine regulation, fibrinolysis and control of proliferation and apoptosis to the group rather than to any one of them. The nuclear entry all of that presupposes was shown for short fluorescence-labeled peptides in HeLa cells Fedoreyeva 2011 — not in a thymocyte and not in a lymphocyte.
And here is the sharpest version of the decomposition problem, from a 2022 cell paper. Five named preparations were tested on THP-1, a human monocytic leukemia line differentiated into macrophages Avolio 2022: Epitalon, Vilon, Thymogen, Thymalin and Chonluten. All 5 suppressed TNF and interleukin-6 release provoked by bacterial lipopolysaccharide and reduced monocyte adhesion to activated endothelial cells. Count what is in that list and what is not: 2 of Thymalin's 3 named short peptides are there — the mixture itself and the Glu-Trp dipeptide sold as Thymogen — and Glu-Asp-Pro is not. The one experiment that came closest to testing this product tested its 2 siblings and left it out.
And there is exactly 1 paper indexed under the name Crystagen, which is 1 more than most of this catalog has and which nobody quotes. It examined immunoprotective effects of short peptides in spleen during aging, comparing Vilon, Thymogen, Crystagen and a fourth peptide Chervyakova 2014. Its finding for this compound has 2 halves and the second half is the interesting one: Crystagen activates B-cells — and does not produce cell renewal in the aging spleen. That is a positive and a negative in 1 sentence, published by the school that sells it, about the specific molecule. The abstract states no species, no model and no effect size, so what can be taken from it is direction and nothing more; it is Russian-language and, like the rest of this literature, unreplicated.
The obstacle, stated as precisely as it can be. The step that has never been taken is decomposition: nobody has shown that the effects of a 3-component preparation belong to any 1 of its components. That is a real experiment with a real design — run the mixture, run each peptide alone, run them in pairs, read the same endpoint — and it is the experiment that would justify or demolish the entire practice of selling Khavinson preparations as isolated peptides. It has not been done for Thymalin and its 3 named peptides, and it has not been done for any other preparation in this catalog either. Until it is, buying Crystagen means buying 1 of 3 named ingredients of something whose evidence was generated whole — with 1 spleen paper on the isolated peptide, which found a B-cell effect and an absence of cell renewal, standing on its own. The outside view is the same as for the rest of the class: the independent systematic review that pooled 24 randomized trials over 2,245 participants rated risk of bias moderate to high and certainty of evidence low to very low, and covered none of these peptides individually Alsulaimani 2021.
What would have to be true, and how you would know it was not
Three predictions. The first is the only one specific to this molecule's chemistry, and it is testable in a way nothing else on this page is.
1. The one paper on this peptide points at B-cells, so a CBC with differential is the floor and a lymphocyte subset panel is the actual test. The spleen work reports B-cell activation without spleen cell renewal Chervyakova 2014, and a total lymphocyte count cannot distinguish a B-cell change from a T-cell change — flow cytometry can, and CD19 or CD20 B-cell percentage is the mechanism-linked number nobody has drawn on this compound. The lymphocyte count and the neutrophil-to-lymphocyte ratio on an ordinary CBC are the cheap floor beneath it. Draw it at baseline, and again after a course — and read it against the season, because a CBC differential in February and a CBC differential in July are not the same measurement in a person who catches respiratory infections. Fibrinogen is the second one worth a baseline, because coagulation markers are what moved in the Thymalin work, and this site retests it every 6 to 12 months when elevated.
2. The proline prediction, which is the novel one. Chemistry says EDP should clear from serum more slowly than Glu-Asp-Gly or Glu-Asp-Leu, because a C-terminal proline blocks the carboxypeptidases and leaves a prolidase-dependent Asp-Pro fragment. If that is right, the same milligram of Crystagen buys more exposure-time than the same milligram of its siblings, and the correct course length for it is different from theirs. Nobody has measured serum stability for any of these 3 tripeptides, so nobody knows — and an in-vitro serum half-life comparison of the 3 is a single afternoon of work that would either confirm this or kill it.
3. The prediction that cuts against the product: an ESR and an hs-CRP should not improve, and a course should not shorten an infection you already have. Thymalin's clinical use was in acutely ill hospitalized patients under supervision. Nothing in that record supports a healthy person taking 1 of its components as a seasonal preventive, and the honest expectation for a healthy adult is that inflammatory markers stay where they were. If ESR or hs-CRP falls during a course, the first explanation to exclude is that whatever was raising it resolved on its own.
What nobody has tested yet
Five experiments, and the first two are the ones this whole market should be embarrassed about.
1. The decomposition experiment. Thymalin's activity is attributed in print to 3 named short peptides. No published work separates their contributions. Mixture, each peptide alone, each pair, 1 endpoint, 1 experiment — and it would settle whether any of the isolated Khavinson peptides deserve to be sold at all. It has never been run.
2. The serum stability comparison. Glu-Asp-Pro, Glu-Asp-Gly and Glu-Asp-Leu differ at exactly 1 position. Incubate all 3 in human serum at 37°C and sample by mass spectrometry over 2 hours. That single experiment would tell you whether the proline does what chemistry says it should, whether these products should share a dosing schedule, and whether the ‘short half-life’ line that every page in this category carries is even the same number for all of them. 0 laboratories have published it.
3. The acid-lability test that decides the oral question. Because the Asp-Pro bond is selectively cleaved under mild acid, this molecule has a specific, predictable failure mode in the stomach. Incubate at pH 1.5 to 3.5 with pepsin for 1 hour and measure what fraction survives. If the answer is near 0%, every oral product built on this sequence is inert by chemistry, which is a stronger statement than any evidence review could make. Nobody has published the number.
4. Nobody has followed up the negative half of the only result this peptide has. B-cell activation without cell renewal is a specific, odd combination: it says the existing cells respond and the population does not expand. If that is right, the effect should be transient and should not accumulate over repeated courses — which is testable by running a B-cell subset panel after 1 course and again after 3, and which would be the first thing anybody has ever asked about the durability of this compound.
5. Nobody has looked at thymic tissue. Thymic involution is measurable on a chest CT and by T-cell receptor excision circle counts, which read out how much genuinely new thymic output a person has. Neither has ever been measured on any product in this family, including Thymalin itself, and the entire immune-rejuvenation claim rests on the assumption that they would move.
Crystagen — its own safety story, not its class's
The class safety block covers injecting peptides generally. Three things here are specific.
Autoimmune disease is the population where an immune-directed peptide is least predictable. The claim being made is modulation of lymphocyte populations. In somebody whose lymphocytes are already attacking their own tissue — Hashimoto's thyroiditis, rheumatoid arthritis, psoriasis, inflammatory bowel disease — a compound with an unknown direction of effect is a coin flip on the thing that is already going wrong. There is no evidence of harm and no evidence of safety, and with 0 human studies of this peptide alone, there is no arm in which either could have been observed.
Anyone on immunosuppression should treat this as an interaction until somebody shows it is not. Transplant medication, biologics for autoimmune disease and cancer immunotherapy all work by setting the immune system to a particular level on purpose. Adding an agent whose stated goal is to move that level, with 0 interaction studies published, is the one combination on this page worth refusing outright rather than monitoring.
The identity risk, which is this compound's own. This product has already been recorded on this site with the wrong sequence. That was a catalog error and it is fixed, but it points at the real problem: the trade name and the sequence are joined by vendor consensus, no lot-level tandem mass spectrometry is published by anybody, and the 359.35 Da figure on this page is computed from the sequence rather than measured from a vial. Ask a vendor for fragmentation data rather than a purity percentage — a purity figure tells you how much of something is in the tube, not which something it is.
Sources read for this page
- Chervyakova NA, et al. Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process. Advances in Gerontology 2014;27(1):[Russian-language] · PMID 28976144
- Avolio F, et al. (co-authors include Khavinson VKh). Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. International Journal of Molecular Sciences 2022;23(7):3607 · PMID 35408963
- Fedoreyeva LI, et al. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow) 2011;76(11):1210–1219 · PMID 22117547
- Kuznik B, Khavinson V, Shapovalov K, Linkova N, Lukyanov S, Smolyakov Yu, Tereshkov P, Shapovalov Yu, Konnov V, Tsybikov N. Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients. Advances in Gerontology 2021;11(4):368–376
- Khavinson VKh, Linkova NS, Chalisova NI, Ivko OM. The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity. Biology Bulletin Reviews 2021;11(4):377–382
- Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules 2021;26(22):7053 · PMID 34834147
- Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences 2022;23(14):7733 · PMID 35887081
- Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules 2023;13(3):552 · PMID 36979488
- Kolchina N, Khavinson V, Linkova N, Yakimov A, Baitin D, Afanasyeva A, Petukhov M. Systematic search for structural motifs of peptide binding to double-stranded DNA. Nucleic Acids Research 2019;47(20):10553–10563 · PMID 31598715
- Alsulaimani RA, Quinn TJ (independent — not the Khavinson group). The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis. Cerebral Circulation – Cognition and Behavior 2021;2:100012 · PMID 36324709
Crystagen — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These are short peptide fragments of organ extracts, and the honest starting point is that the mechanism itself is not established in a way that lets anyone predict harm precisely. The proposal is gene-regulatory — short peptides binding DNA and modulating transcription in a tissue-specific way. If that is what they do, the theoretical concern is influencing transcription in tissue you were not aiming at.
- In practice the doses are tiny, the peptides are short, and they are degraded quickly — which is also the argument that they may do very little at all. Those two possibilities are the same uncertainty viewed from opposite ends, and you should hold both.
What has actually been reported
- Decades of Russian clinical use with a strikingly clean tolerability record — injection-site reactions and little else reported.
- That record comes almost entirely from one research school, is largely unreplicated outside it, and safety data from a group with an interest in the outcome is worth less than the same data from a skeptic. This is not an accusation; it is how evidence weighting works.
How to reduce the risk
Same mechanism as the prediction.
- Follow the course printed on the label rather than running continuously. These are the one class in the Vault where a duration is STATED rather than inferred, and it is typically 10–20 days repeated a few times a year. Read the box.
- Run one at a time. They are cheap and it is tempting to stack six. If something changes, a stack of six tells you nothing about which one did it — and given the evidence base, attribution is the entire value of your own experiment.
- Decide your endpoint before you start, and make it a marker or a measurable symptom rather than a feeling. With a compound class this under-evidenced, an unfalsifiable endpoint means you will conclude it worked no matter what happened.
- Buy from a source that publishes third-party testing. Where the molecule itself is uncertain, identity and purity are the only variables you can actually control.
What it does to your bloodwork
A fact about the assay.
- Test the ORGAN, not the peptide. A thymic peptide is judged on immune markers, a pineal one on sleep and IGF-1, a vascular one on lipids and inflammatory markers. There is no assay for the compound itself.
Don't run this if
- Pregnancy — not because of a specific finding, but because nobody has studied it and the mechanism claim is transcriptional.
- Active malignancy, on the same reasoning as any tissue-growth signal: unproven, mechanistically arguable, and not worth finding out.
The honest unknown
- Essentially everything a skeptic would want: independent replication, pharmacokinetics, and whether the oral forms survive digestion at all. Unproven is not the same as ineffective — but here it is a large unproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Crystagen — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Crystagen moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
These are short peptide fragments given in microgram amounts and there is no mechanism predicting a specific marker shift. Listing markers here would be padding.
What to do: Test the organ system the bioregulator is aimed at, not a generic panel — that is the only measurement that would tell you anything.
The evidence base here is almost entirely one research group's, largely in Russian, and rarely replicated independently. That is the single most important thing to know before running a course, and it is more useful than any interaction list.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Crystagen in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Crystagen
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Crystagen — frequently asked questions
What is Crystagen?
Crystagen (Glu-Asp-Pro (immune bioregulator)) is a longevity & bioregulators research compound. Khavinson immune bioregulator — Glu-Asp-Pro, one of the three short peptides this school names as constituents of the thymus preparation Thymalin, proposed to shift gene expression in immune tissue.
Is the full Crystagen protocol on this page?
The reported research dose is on this page, along with how Crystagen works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Crystagen?
Crystagen has an approximate half-life of ~15-30 min, which is part of what determines how often it's dosed.
What's the evidence behind Crystagen?
Current evidence level: Russian studies; limited. Crystagen is offered for research purposes only and is not an approved medicine.
Crystagen inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Crystagen is used for
Crystagen appears under 2 goals in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
Crystagen is the immune arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.